Among the variant peptides with high levels in non-responders was a mutated peptide from the B2M protein, which has been previously linked to ICI therapy resistance in melanoma.29 This highlights how variant peptides could be used in a liquid biopsy approach to detect tumor-specific proteins in plasma. This evidence concerns the gene B2M and neoplasm.